Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world to ...

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling ...

While Novo Nordisk and Pfizer intensify their plays, Lilly’s early lead in GLP-1 treatments has put it in a category all its ...

The company that sells Ozempic and Wegovy, drugs known for promoting easy weight loss, is now selling the products at Costco.

Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

However, the Eli Lilly has roared back and is up 32% year to date. The stock price now exceeds $1,000, which could ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Eli Lilly becomes first pharma major to enter $1 trillion M-Cap club; stock price rises 1.7% on Wall St. — Details here ...